Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Chen

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
The Oncologist|March 13, 2020
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination TherapyLeyre Zubiri, Ian M Allen, Martin S Taylor, et al.
Nature|June 6, 2020
Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunityBarbara Maier, Andrew M Leader, Steven T Chen, et al.
Nature|April 10, 2020
A conserved dendritic-cell regulatory program limits antitumour immunityBarbara Maier, Andrew M Leader, Steven T Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Nature|June 17, 2021
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cellsMaría Casanova-Acebes, Erica Dalla, Andrew M Leader, et al.
Nature Medicine|May 7, 2021
BRAF<sup>V600E</sup>-induced senescence drives Langerhans cell histiocytosis pathophysiologyCamille Bigenwald, Jessica Le Berichel, C Matthias Wilk, et al.
Nature Immunology|January 21, 2025
Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancerMeriem Belabed, Matthew D Park, Cédric M Blouin, et al.
Journal for Immunotherapy of Cancer|September 21, 2021
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancerLeyre Zubiri, Gabriel E Molina, Meghan J Mooradian, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
The Oncologist|March 13, 2020
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination TherapyLeyre Zubiri, Ian M Allen, Martin S Taylor, et al.
Nature|June 6, 2020
Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunityBarbara Maier, Andrew M Leader, Steven T Chen, et al.
Nature|April 10, 2020
A conserved dendritic-cell regulatory program limits antitumour immunityBarbara Maier, Andrew M Leader, Steven T Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Nature|June 17, 2021
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cellsMaría Casanova-Acebes, Erica Dalla, Andrew M Leader, et al.
Nature Medicine|May 7, 2021
BRAF<sup>V600E</sup>-induced senescence drives Langerhans cell histiocytosis pathophysiologyCamille Bigenwald, Jessica Le Berichel, C Matthias Wilk, et al.
Nature Immunology|January 21, 2025
Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancerMeriem Belabed, Matthew D Park, Cédric M Blouin, et al.
Journal for Immunotherapy of Cancer|September 21, 2021
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancerLeyre Zubiri, Gabriel E Molina, Meghan J Mooradian, et al.
Pageof 16